US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch

 
• By Dave Wallace

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Risk_Scales
After Weighing Genentech’s Arguments, The Court Decided Against An Injunction • Source: Shutterstock

Genentech has been denied its request for a US appeals court to grant an injunction preventing Amgen from selling its Kanjinti (trastuzumab-anns) biosimilar rival to the originator’s Herceptin.

“Our determination is governed by four factors,” the US Court of Appeals for the Federal Circuit stated

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products